Skip to main content

Latest news

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Breaking headlines, in-depth features, hot topic review articles, and 

the latest from major international conferences brought to you by

Editors' pick

12-09-2017 | Rheumatoid arthritis | Feature | Article

At a glance: Trials evaluating baricitinib in RA

Our quick guide to the phase II and III trials of baricitinib for the treatment of rheumatoid arthritis. 

Latest headlines

18-09-2017 | Rheumatoid arthritis | News

RA disease activity and severity play ‘important role’ in reducing CVD risk

Targeting factors such as inflammation and disease activity in patients with rheumatoid arthritis could help reduce their risk for cardiovascular disease, study findings suggest.


Ann Rheum Dis 2017; Advance online publication

15-09-2017 | Rheumatoid arthritis | News

News in brief

Predictors of medication adherence in RA patients identified

A Canadian research team has pinpointed several sociodemographic, disease, and treatment parameters associated with adherence to medication in patients with rheumatoid arthritis.

13-09-2017 | Giant cell arteritis | News

News in brief

Herpes zoster infection ‘one potential trigger’ for giant cell arteritis

Results of a US study suggest that herpes zoster infection is associated with an increased risk for giant cell arteritis, but antiviral treatment and vaccination are unlikely to reduce this risk.

11-09-2017 | Gout | News

Weight loss supported for obese patients with gout

Evidence from a systematic review suggests that weight loss is likely to be beneficial for overweight and obese patients with gout.


Ann Rheum Dis 2017; Advance online publication

In depth

19-07-2017 | Rheumatoid arthritis | Feature | Article

JAK inhibitors for RA: Professor Roy Fleischmann speaks to medwireNews

Roy Fleischmann talks to medwireNews about the need for JAK inhibitors and their potential impact on the rheumatoid arthritis treatment landscape.

04-08-2017 | Rheumatoid arthritis | Article

At a glance: The ORAL trials of tofacitinib for the treatment of RA

Our quick-reference guide to the seven ORAL trials of tofacitinib for the treatment of rheumatoid arthritis that have been completed to date.

medwireNews@EULAR 2017

medwireNews was at EULAR 2017. Click through for research news, conference highlights, and expert interviews from Madrid.

image credits